Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
03:12pm, Monday, 09'th Jun 2025
Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy AUSTIN, Texas , June 9, 2025 /PRNewswire/ -- ADAR1
Keros Announces Return of $375 Million in Excess Capital to Stockholders
06:55am, Monday, 09'th Jun 2025
Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 Concludes Strategic Alternatives Review and Provides Update on Development of KER-065
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
04:01pm, Friday, 06'th Jun 2025
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025
BofA says Keros cost reduction 'disappoints,' still sees reasons to like story
01:14pm, Thursday, 29'th May 2025
04 Jun
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
06:55am, Thursday, 29'th May 2025
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeu
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees
01:45pm, Tuesday, 27'th May 2025
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth
08:00am, Wednesday, 21'st May 2025
ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting AUSTIN, Texas , May 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1
AUSTIN, Texas , May 12, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Compan
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
08:00am, Monday, 12'th May 2025
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel the
Keros Reinforces Commitment to Maximizing Stockholder Value
05:31pm, Thursday, 08'th May 2025
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 202
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders
02:10pm, Thursday, 08'th May 2025
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth AUSTIN, Texas , May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates
08:10pm, Tuesday, 06'th May 2025
Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $3.62 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $1.21 per share a year
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
04:01pm, Tuesday, 06'th May 2025
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and comm
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
01:00pm, Friday, 11'th Apr 2025
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
